ArticleTranslational cancer research2019
Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Radiomic and Genomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review.Journal of medical Internet research · 2021Pooled it
- The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals.bioRxiv : the preprint server for biology · 2026Article
- Inflammation-immune-nutrition biomarkers and PSA variability: A population-based study on the clinical potential of the CALLY index.Biomedical reports · 2025Article
- Peritumoral CD117 Immunopositive Mast Cell Density in Prostatic Adenocarcinoma and Its Correlation with the New Gleason Score.Indian journal of surgical oncology · 2025Article
- Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2024Article
- A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLactate dehydrogenase (LDH) and C-reactive protein (CRP) are biomarkers of inflammation commonly used in medicine. The aim was to evaluate the utility of serum LDH and CRP levels for diagnosis of prostate cancer (PC) in men with nonspecific elevations of serum total prostate specific antigen (PSA) levels.
methodsThe following serum biomarkers were measured in patients with PSA between 4 and 10 ng/mL: LDH, CRP and free-PSA. The free-to-total serum PSA ratio (%fPSA) was (free-PSA/PSA) ×100. Patients were classified into two groups according to diagnosis of prostate biopsy: PC and NOT PC patients. Logistic regression was used for develop a probabilistic model to predict PC patients. Diagnostic accuracy was determined using receiver operating characteristic (ROC) curves, calculating the area under the ROC curve (AUC).
resultsWe studied 232 patients with ages between 43 and 98 years old (median =72), 200 NOT PC and 32 PC patients. CRP was not statistically significantl to differentiate between PC and NOT PC patients. Probabilistic model (%) was 100× (1+ e
conclusionsCRP was not useful to differentiate benign from malignant prostate disease, in contrast LDH could be used for diagnosis of PC. A probabilistic model using LDH and %fPSA can improve the diagnostic accuracy in patients with PSA between 4 and 10 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.